Vantictumab (Anti-FZD)
Product Specifications
CAS Number
1345009-45-1
Synonyms
OMP-18R5
Target
Wnt/beta-catenin
Applications
Cytoskeletal Signaling
Additionnal Information
Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC742853-100 1x 100 µL
CD54 / ICAM-1 (15.2), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC700391-500 1x 500 µL
CD81 / TAPA-1 (1.3.3.22), CF770 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740304-100 1x 100 µL
CD106 / VCAM1 (B-K9), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470218-500 1x 500 µL
CD100 (Semaphorin-4D) (A8), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 